1. The company has a large room for product growth, and its marketing work is developing rapidly, which is expected to achieve higher growth; Qinghai Pharmaceutical, an anesthetic industrial enterprise, will resume its investment income growth in 2009, and Yichang Renfu will continue to be in a period of rapid growth.
2. On February 4th, 2009, the company received a notice from Sinopharm Holdings Co., Ltd., the largest shareholder, that the company sold 65,438+0,359,520 shares through the trading system of Shanghai Stock Exchange from October 25th to that day in 2008. At present, it still holds107,724,287 shares, accounting for 45% of the company's total share capital.
3. Main financial indicators of the company in the first three quarters of 2009: earnings per share of 0.3938 yuan, net assets per share of 2.0800 yuan, return on net assets of 18.9500%, and operating income of 3877620207.0000 yuan, up or down19.2080% year-on-year; The net profit attributable to shareholders of listed companies 18855 1545.4438+0 (yuan) increased or decreased by 23.7468% year-on-year.
4. The company's profit distribution in 2008 and capitalization of capital reserve. This plan is: send 5 shares for every 65,438+00 shares, and send 65,438+0.5 yuan (including tax) after adding 5 shares. Registration date: June 2, 2009, ex-dividend date: June 3, 2009.
5. The actual controller of the company, China Pharmaceutical Group Company, is the only purchasing, storage and dispatching unit of influenza A vaccine (H 1N 1) designated by the Ministry of Industry and Information Technology, and China Pharmaceutical Group Company has determined the company as the specific implementation unit of vaccine procurement, storage and dispatching.